Kate Kelley, MD, UCSF Health

Articles by Kate Kelley, MD, UCSF Health

Emerging Therapies for HCC Management

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Metastatic HCC Unmet Needs

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

I/O Second-Line Treatment

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

REACH and REACH2 Trial Overview

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Second-Line Therapy: Monoclonal Antibody

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Second-Line Sequencing After IMbrave150 Regimen

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

R/R HCC: Second-Line Options

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Frontline I/O: Clinical Trial Overviews

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Frontline Therapy: Promising I/O Combinations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Phase 3 IMbrave150 Trial

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Frontline Decision Factors for Metastatic Disease

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Treatment Algorithm: Asia and Europe

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Transitioning From Locoregional to Systemic Therapy

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Diagnosis and Prognosis

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

The Evolving Role of Medical Oncologists and Hepatologists

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Global Screening Programs for At-Risk Populations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Etiologic Risk Factors and Global Prevalence

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Latest Updated Articles

Frontline I/O: Clinical Trial Overviews
June 29th 2020
R/R HCC: Second-Line Options
June 29th 2020
REACH and REACH2 Trial Overview
June 29th 2020
I/O Second-Line Treatment
June 29th 2020
HCC Treatment Algorithm: Asia and Europe
June 29th 2020
Frontline Therapy: Promising I/O Combinations
June 29th 2020

Kate Kelley, MD, UCSF Health

Articles by Kate Kelley, MD, UCSF Health

Emerging Therapies for HCC Management

Metastatic HCC Unmet Needs

I/O Second-Line Treatment

REACH and REACH2 Trial Overview

Second-Line Therapy: Monoclonal Antibody

Second-Line Sequencing After IMbrave150 Regimen

R/R HCC: Second-Line Options

Frontline I/O: Clinical Trial Overviews

Frontline Therapy: Promising I/O Combinations

Phase 3 IMbrave150 Trial

Frontline Decision Factors for Metastatic Disease

HCC Treatment Algorithm: Asia and Europe

Transitioning From Locoregional to Systemic Therapy

HCC Diagnosis and Prognosis

The Evolving Role of Medical Oncologists and Hepatologists

HCC Global Screening Programs for At-Risk Populations

HCC Etiologic Risk Factors and Global Prevalence

Latest Updated Articles

Trending on OncLive

Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

Five Under 5: Top Oncology Videos for the Week of 6/28

The OncFive: Top Oncology Articles for the Week of 6/28

Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma